# DC Vaccination for Post-remission Therapy in AML

> **NCT02405338** · PHASE1,PHASE2 · COMPLETED · sponsor: **Medigene AG** · enrollment: 20 (estimated)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **BIOLOGICAL:** WT1/PRAME vaccination

## Key facts

- **NCT ID:** NCT02405338
- **Lead sponsor:** Medigene AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-03
- **Primary completion:** 2019-11
- **Final completion:** 2019-11
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2020-07-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02405338

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02405338, "DC Vaccination for Post-remission Therapy in AML". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02405338. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*